Abstract
摘要
相似文献
1
[In process].[正在处理中]。
Med Monatsschr Pharm. 2017 Mar;40(3):133-4.
2
Incretins and risk of neoplasia.肠促胰岛素与肿瘤形成风险
BMJ. 2013 Jun 10;346:f3750. doi: 10.1136/bmj.f3750.
3
Pancreatic safety of incretin-based drugs--FDA and EMA assessment.基于肠促胰岛素药物的胰腺安全性——美国食品药品监督管理局和欧洲药品管理局的评估
N Engl J Med. 2014 Feb 27;370(9):794-7. doi: 10.1056/NEJMp1314078.
4
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.基于肠促胰岛素的降糖药物与急性胰腺炎和/或胰腺癌风险：心血管结局试验的可靠数据
Diabetes Obes Metab. 2017 Sep;19(9):1327-1328. doi: 10.1111/dom.12981. Epub 2017 May 22.
5
The safety of incretin based drug treatments for type 2 diabetes.基于肠促胰岛素的2型糖尿病药物治疗的安全性。
BMJ. 2016 Feb 17;352:i801. doi: 10.1136/bmj.i801.
6
An updated review on cancer risk associated with incretin mimetics and enhancers.关于肠促胰岛素类似物和增强剂相关癌症风险的最新综述。
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(1):67-124. doi: 10.1080/10590501.2015.1003496.
7
Incretins: cardiovascular safety and rationale for use.肠促胰岛素：心血管安全性及使用原理
Cardiovasc J Afr. 2013 Mar;24(2):46.
8
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.诺和诺德回应《英国医学杂志》关于肠促胰岛素与胰腺损伤的调查。
BMJ. 2013 Jul 10;347:f4386. doi: 10.1136/bmj.f4386.
9
Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.《英国医学杂志》调查发现，2型糖尿病药物的潜在危害一直被忽视。
BMJ. 2013 Jun 11;346:f3782. doi: 10.1136/bmj.f3782.
10
[Incretin-based therapy in type 2 diabetes does not increase the risk of hospitalization for heart failure].[基于肠促胰岛素的2型糖尿病治疗不会增加因心力衰竭住院的风险]
Praxis (Bern 1994). 2016 Jun 22;105(13):785-6. doi: 10.1024/1661-8157/a002393.
Zotero 插件